A personalized drug screening platform using patient-derived neuroendocrine tumor cultures identified individual treatment responses, advancing precision oncology for these rare cancers.
23 patient tumors testedPersonalized drug screening identifies individual treatment responses in rare neuroendocrine cancers
What the researchers found
Personalized drug screening in patient-derived GEP-NEN cultures successfully identified individual tumor drug responses, demonstrating precision oncology feasibility.
Why it matters
Rare cancers like GEP-NENs lack the large trial data that guides treatment of common cancers. Personalized screening could match individual patients with their most effective therapy.
How the study worked
Standardized drug screening platform using 23 patient-derived GEP-NEN primary cultures (16/23 from metastatic tumors), testing responses to multiple therapeutic agents.
What this study cannot tell us
Small sample (23 patients); primary cultures may not fully recapitulate in vivo tumor behavior; clinical correlation of in vitro drug sensitivity needs validation.
How to read the evidence
Translational research study — demonstrates platform feasibility but clinical outcome correlation is pending.
When this study was published
Published 2026 in JCEM.
The bigger picture
This platform approach could be applied to other rare cancers where large randomized trials are impractical, enabling precision medicine even with small patient populations.
Questions still open
- Do in vitro drug sensitivity results predict actual clinical response in patients?
- Can this platform be scaled for routine clinical use in GEP-NEN management?
Common questions
What are neuroendocrine tumors?
How does personalized drug screening work?
Read the original research
Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms.
The Journal of clinical endocrinology and metabolism
Citation
Auernhammer, Christoph J; Wang, Katharina; Maccio, Umberto; Knösel, Thomas; Hungbauer, Maximilian P; Schilbach, Katharina; Maurer, Julian; Peischer, Lea; Reul, Astrid; Kuzmenko, Elena; Luca, Edlira; Hamati, Julia; Vetter, Diana; Oberholzer, Jose; Fritsch, Ralph; Pacak, Karel; Grossman, Ashley B; Beuschlein, Felix; Reincke, Martin; Hantel, Constanze; Zitzmann, Kathrin; Nölting, Svenja. (2026). Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms.. The Journal of clinical endocrinology and metabolism. https://doi.org/10.1210/clinem/dgaf705